IP Library Granted Patent US 11,395,822
Granted Patent B2
US 11,395,822 · App. 16/625,126 · Granted Jul 26, 2022

Methods for treating Huntington's disease

Inventors: Anuradha Bhattacharyya (Edison, NJ); Minakshi B. Jani (Iselin, NJ)
Assignee: PTC THERAPEUTICS, INC.
A61K31/519A61K31/5025A61K31/517A61K31/551A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,395,822
App. No.
16/625,126
Granted
Jul 26, 2022
Kind
B2
Abstract

The present description relates to a method or use of a compound for treating or ameliorating HD (Huntington's Disease) in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I): or a form thereof, wherein R 1 , R 2 , R a , R b and R c are as defined herein. In particular, the present description relates to a method of use of a compound of Formula (I) or a form or composition thereof for treating or ameliorating HD in a subject in need thereof comprising, administering an effective amount of the compound or a form or composition thereof to the subject.

Claims (9)

1. A method of treating or ameliorating HD in a subject in need thereof comprising, administering to the subject an effective amount of a compound or salt form thereof selected from the group consisting of:

(R)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(3-methylpiperazin-l-yl)-4H -pyrido[1,2-a]pyrimidin-4-one

2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(3,3-dimethylpiperazin-l-yl)-4H -pyrido[1,2-a]pyrimidin-4-one

2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-9-methyl-7-(4,7-diazaspiro[2.5]octan-7-yl) -4H-pyrido[1,2-a]pyrimidin-4-one.

2. The method of claim 1 , wherein the effective amount of the compound is in a range of from about 0.001 mg/kg/day to about 500 mg/kg/day.

3. The method of claim 1 , wherein the compound or salt form thereof is in admixture with one or more pharmaceutically acceptable excipients to form a pharmaceutical composition.

4. The method of claim 1 , wherein the compound or salt form thereof is (R)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(3-methylpiperazin-l-yl)-4H-pyrido[1,2-a]pyrimidin-4-one.

5. The method of claim 1 , wherein the compound or salt form thereof is 2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(3,3-dimethylpiperazin-l-yl)-4H-pyrido[1,2-a]pyrimidin-4-one.

6. The method of claim 1 , wherein the compound or salt form thereof is 2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-9-methyl-7-(4,7-diazaspiro[2.5]octan-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2020
From: BHATTACHARYYA, ANURADHA; JANI, MINAKSHI B
To: PTC THERAPEUTICS, INC.
Reel/Frame 051906/0404 →
Continuity (2)
Provisional Application 62525838 · Jun 28, 2017
Related Publication 20200147087A1 · May 14, 2020